Buy American Act compliance
Buy American Act compliance in Healthcare & Life Sciences is increasingly enforced territory, not background noise. The U.S. Department of Defense and the U.S. Department of Health and Human Services have both tightened domestic content scrutiny for medical supplies and pharmaceutical inputs under the Federal Acquisition Regulation's Part 25 framework, with HHS supply chain directives post-Executive Order 13944 extending BAA obligations deeper into federal contractor tiers. Life sciences compliance teams are currently mapping device and drug ingredient sourcing against end-product domestic content thresholds before contract renewals hit.
Watch
- FAR Part 25 domestic content thresholds: proposed increase to 75% now in rulemaking
- HHS supplier attestation requirements for critical drug inputs under E.O. 13944 successor actions
- DoD medical supply contracts: increased scrutiny of foreign component waivers at renewal
- Class waiver expirations for PPE and surgical supplies filed pre-2022
- FDA-registered facility sourcing: whether domestic registration satisfies BAA end-product tests
Recent material activity in Healthcare & Life Sciences
Active monitoring in place across Healthcare & Life Sciences. Material developments related to buy american act compliance will appear here as they are published.